ArticleJournal of hematology & oncology2019

CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.

Michele Stanchina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.